Joel Greenblatt’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.2M | Buy |
433,146
+74,644
| +21% | +$13.3M | 0.23% | 31 |
|
|
2026
Q1 | $61.8M | Buy |
358,502
+68,986
| +24% | +$12.8M | 0.19% | 50 |
|
|
2025
Q4 | $57.8M | Sell |
289,516
-26,239
| -8% | -$4.76M | 0.21% | 43 |
|
|
2025
Q3 | $49.4M | Buy |
315,755
+46,594
| +17% | +$7.4M | 0.22% | 32 |
|
|
2025
Q2 | $40.8M | Buy |
269,161
+114,384
| +74% | +$15.3M | 0.24% | 23 |
|
|
2025
Q1 | $23.3M | Buy |
154,777
+31,087
| +25% | +$5.21M | 0.19% | 63 |
|
|
2024
Q4 | $22.8M | Buy |
123,690
+46,313
| +60% | +$8.92M | 0.22% | 51 |
|
|
2024
Q3 | $15.2M | Buy |
77,377
+26,254
| +51% | +$5.46M | 0.16% | 128 |
|
|
2024
Q2 | $10.6M | Buy |
51,123
+28,064
| +122% | +$6.36M | 0.14% | 171 |
|
|
2024
Q1 | $6.25M | Buy |
23,059
+6,093
| +36% | +$1.46M | 0.09% | 290 |
|
|
2023
Q4 | $4.01M | Buy |
16,966
+889
| +6% | +$175K | 0.07% | 366 |
|
|
2023
Q3 | $3.15M | Buy |
16,077
+1,844
| +13% | +$379K | 0.07% | 417 |
|
|
2023
Q2 | $2.99M | Sell |
14,233
-1,832
| -11% | -$365K | 0.07% | 428 |
|
|
2023
Q1 | $3.24M | Buy |
16,065
+3,274
| +26% | +$742K | 0.08% | 336 |
|
|
2022
Q4 | $2.79M | Sell |
12,791
-2,718
| -18% | -$594K | 0.08% | 317 |
|
|
2022
Q3 | $3.05M | Sell |
15,509
-1,563
| -9% | -$337K | 0.09% | 264 |
|
|
2022
Q2 | $3.65M | Sell |
17,072
-2,112
| -11% | -$516K | 0.12% | 209 |
|
|
2022
Q1 | $5.45M | Buy |
19,184
+14,360
| +298% | +$4.43M | 0.17% | 153 |
|
|
2021
Q4 | $1.82M | Sell |
4,824
-1,734
| -26% | -$674K | 0.06% | 372 |
|
|
2021
Q3 | $2.71M | Buy |
6,558
+1,268
| +24% | +$527K | 0.11% | 242 |
|
|
2021
Q2 | $1.96M | Buy |
5,290
+1,753
| +50% | +$585K | 0.08% | 317 |
|
|
2021
Q1 | $1.02M | Sell |
3,537
-3,457
| -49% | -$961K | 0.05% | 461 |
|
|
2020
Q4 | $1.75M | Sell |
6,994
-3,769
| -35% | -$898K | 0.06% | 386 |
|
|
2020
Q3 | $2.44M | Buy |
10,763
+2,342
| +28% | +$486K | 0.08% | 319 |
|
|
2020
Q2 | $1.47M | Sell |
8,421
-20,059
| -70% | -$3.2M | 0.04% | 476 |
|
|
2020
Q1 | $3.59M | Buy |
28,480
+26,665
| +1,469% | +$4M | 0.1% | 290 |
|
|
2019
Q4 | $277K | Buy |
+1,815
| New | +$251K | 0.01% | 953 |
|
|
2019
Q3 | – | Sell |
-2,248
| Closed | -$319K | – | 1110 |
|
|
2019
Q2 | $319K | Sell |
2,248
-7,863
| -78% | -$1.07M | 0.01% | 940 |
|
|
2019
Q1 | $1.47M | Sell |
10,111
-23,794
| -70% | -$3.13M | 0.02% | 554 |
|
|
2018
Q4 | $3.84M | Buy |
+33,905
| New | +$4.25M | 0.06% | 380 |
|
|
2018
Q2 | – | Sell |
-2,750
| Closed | -$294K | – | 905 |
|
|
2018
Q1 | $294K | Buy |
+2,750
| New | +$296K | ﹤0.01% | 813 |
|
|
2017
Q4 | – | Sell |
-45,906
| Closed | -$4.96M | – | 956 |
|
|
2017
Q3 | $4.96M | Buy |
45,906
+43,607
| +1,897% | +$4.48M | 0.07% | 361 |
|
|
2017
Q2 | $233K | Sell |
2,299
-113,999
| -98% | -$10.5M | ﹤0.01% | 875 |
|
|
2017
Q1 | $10.5M | Buy |
116,298
+113,548
| +4,129% | +$9.64M | 0.13% | 250 |
|
|
2016
Q4 | $210K | Buy |
+2,750
| New | +$209K | ﹤0.01% | 883 |
|
|
2016
Q3 | – | Sell |
-11,856
| Closed | -$977K | – | 944 |
|
|
2016
Q2 | $977K | Sell |
11,856
-58,371
| -83% | -$4.81M | 0.01% | 631 |
|
|
2016
Q1 | $5.33M | Buy |
+70,227
| New | +$5.2M | 0.06% | 418 |
|
|
2015
Q4 | – | Sell |
-29,055
| Closed | -$1.85M | – | 884 |
|
|
2015
Q3 | $1.85M | Buy |
+29,055
| New | +$2.09M | 0.02% | 555 |
|
|
2015
Q1 | – | Sell |
-4,028
| Closed | -$256K | – | 924 |
|
|
2014
Q4 | $256K | Buy |
+4,028
| New | +$253K | ﹤0.01% | 863 |
|
|
2014
Q3 | – | Sell |
-11,280
| Closed | -$604K | – | 998 |
|
|
2014
Q2 | $604K | Buy |
+11,280
| New | +$619K | 0.01% | 750 |
|
|
2014
Q1 | – | Sell |
-21,759
| Closed | -$1.15M | – | 1018 |
|
|
2013
Q4 | $1.15M | Sell |
21,759
-19,695
| -48% | -$989K | 0.03% | 602 |
|
|
2013
Q3 | $1.92M | Sell |
41,454
-8,733
| -17% | -$401K | 0.06% | 446 |
|
|
2013
Q2 | $2.06M | Buy |
+50,187
| New | +$2.15M | 0.09% | 346 |
|
Other funds holding CRL
AI
Joel Greenblatt's CRL Position: Q2 2026 in Review
Joel Greenblatt increased its Charles River Laboratories (CRL) stake by 21% in Q2 2026, buying an estimated $13.3M and bringing the position to 433,146 shares worth $98.2M. The position accounts for 0.23% of the portfolio, ranked #31.
Joel Greenblatt first reported a position in CRL in Q2 2013 and has held it in 43 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Joel Greenblatt held 433,146 shares of Charles River Laboratories worth $98.2M as of Q2 2026.
- Joel Greenblatt bought 74,644 Charles River Laboratories shares in Q2 2026, an estimated $13.3M.
- Charles River Laboratories made up 0.23% of Joel Greenblatt's portfolio in Q2 2026, its #31 holding.
- Joel Greenblatt first reported a position in Charles River Laboratories in Q2 2013 and has held it in 43 quarters since.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.